Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular
transition into S phase and are important for the initiation, growth and survival of many …

Cyclin-dependent kinases (Cdks) are the catalytic subunits of a family of mammalian
heterodimeric serine/threonine kinases that have been implicated in the control of cell-cycle …

Purpose MONARCH 2 (ClinicalTrials. gov identifier: NCT02107703) compared the efficacy
and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus …

We evaluated the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor
activity of abemaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDK) 4 …

Objective Advanced hepatocellular carcinoma (HCC) is a lethal malignancy with limited
treatment options. Palbociclib, a well-tolerated and selective CDK4/6 inhibitor, has shown …

PD 0332991 is a highly specific inhibitor of cyclin-dependent kinase 4 (Cdk4)(IC50, 0.011
μmol/L) and Cdk6 (IC50, 0.016 μmol/L), having no activity against a panel of 36 additional …

Cyclin D-dependent kinases (CDK4 and CDK6) are positive regulators of cell cycle entry
and they are overactive in the majority of human cancers. However, it is currently not …

Entry into, progression through, and exit from the G1 phase of the mammalian cell cycle in
response to extracellular mitogenic cues are presumed to be governed by cyclin-dependent …

In contrast to its close homolog CDK4, the cell cycle kinase CDK6 is expressed at high
levels in lymphoid malignancies. In a model for p185 BCR-ABL+ B-acute lymphoid …

Abstract Cyclin-dependent kinases 4 and 6 (CDK4/6) phosphorylate and inhibit
retinoblastoma (RB) family proteins. Hyperphosphorylated RB releases E2F transcription …